September 21, 2022

  EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications – Neflamapimod demonstrates that it reverses the neurodegenerative process in the basal forebrain cholinergic system in animal models – – Phase 2a data in Dementia with Lewy Bodies show positive effects of neflamapimod on […]

November 10, 2021

EIP Pharma announces that final results of the AscenD-LB phase 2 clinical study demonstrates neflamapimod has disease-modifying potential in dementia with Lewy Bodies   Results presented at 14th Clinical Trials in Alzheimer’s Disease (CTAD) meeting in Boston   Neflamapimod treatment led to significant improvement relative to placebo in cognition, motor function, and cognition & function […]

November 4, 2021

Final results of the AscenD-LB clinical study informs on disease-modifying potential of neflamapimod in dementia with Lewy bodies Presentations at 14th Clinical Trials in Alzheimer’s Disease Meeting, November 9-12, 2021 BOSTON, Nov. 4, 2021 /PRNewswire/ — EIP Pharma Inc., a clinical-stage pharma company focused on the development of disease-modifying treatments for dementia and neurodegenerative diseases announces that the […]

November 10, 2021